Role of PET in the evaluation and understanding of coronary physiology

Journal of Nuclear Cardiology

Volumn 14, Issue 4 SPEC. ISS., 2007, Pages 589-603

  Schindler, Thomas H ^a,b   Zhang, Xiao Li ^b   Vincenti, Gabriella ^a   Mhiri, Leila ^a   Lerch, René ^a   Schelbert, Heinrich R ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCHOLINE; ADENOSINE; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATE; ADIPOCYTOKINE; AMMONIA N 13; ARGININE; ASCORBIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOBUTAMINE; ESTROGEN; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; PAPAVERINE; RUBIDIUM 82; SIMVASTATIN; WATER O 15;

ACUTE CORONARY SYNDROME; ADRENERGIC STIMULATION; ANGIOCARDIOGRAPHY; CARDIOVASCULAR AUTOREGULATION; COLD PRESSOR TEST; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY RISK; ENDOTHELIAL DYSFUNCTION; HALF LIFE TIME; HEART MUSCLE BLOOD FLOW; HEART SCINTISCANNING; HEART VENTRICLE WORK; HEMODYNAMICS; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREMIA; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW;

EID: 34547403279     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2007.05.006     Document Type: Review

References (127)

1. Kuhle W.G., Porenta G., Huang S.C., Buxton D., Gambhir S.S., Hansen H., et al. Quantification of regional myocardial blood flow using 13N-ammonia and reoriented dynamic positron emission tomographic imaging. Circulation 86 (1992) 1004-1017
2. Kaufmann P.A., and Camici P.G. Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med 46 (2005) 75-88
3. Schelbert H.R., Phelps M.E., Huang S.C., MacDonald N.S., Hansen H., Selin C., et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation 63 (1981) 1259-1272
4. Bergmann S.R., Fox K.A., Rand A.L., McElvany K.D., Welch M.J., Markham J., et al. Quantification of regional myocardial blood flow in vivo with H215O. Circulation 70 (1984) 724-733
5. Camici P.G., and Crea F. Coronary microvascular dysfunction. N Engl J Med 356 (2007) 830-840
6. rd ed. (2005), Mosby, Philadelphia 399-412
7. Ganz P., and Vita J.A. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 108 (2003) 2049-2053
8. Widlansky M.E., Gokce N., Keaney Jr. J.F., and Vita J.A. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42 (2003) 1149-1160
9. Schindler T.H., Nitzsche E.U., Schelbert H.R., Olschewski M., Sayre J., Mix M., et al. Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. J Am Coll Cardiol 45 (2005) 1505-1512
10. Lerman A., and Zeiher A.M. Endothelial function: cardiac events. Circulation 111 (2005) 363-368
11. Schindler T.H., Hornig B., Buser P.T., Olschewski M., Magosaki N., Pfisterer M., et al. Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms. Arterioscler Thromb Vasc Biol 23 (2003) 495-501
12. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
13. Britten M.B., Zeiher A.M., and Schachinger V. Microvascular dysfunction in angiographically normal or mildly diseased coronary arteries predicts adverse cardiovascular long-term outcome. Coron Art Dis 15 (2004) 259-264
14. Cecchi F., Olivotto I., Gistri R., Lorenzoni R., Chiriatti G., and Camici P.G. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349 (2003) 1027-1035
15. Schindler T.H., Nitzsche E.U., Munzel T., Olschewski M., Brink I., Jeserich M., et al. Coronary vasoregulation in patients with various risk factors in response to cold pressor testing: contrasting myocardial blood flow responses to short- and long-term vitamin C administration. J Am Coll Cardiol 42 (2003) 814-822
16. Hattori N., Schnell O., Bengel F.M., Rihl J., Nekolla S.G., Drzezga A.E., et al. Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus. Eur J Nucl Med Mol Imaging 29 (2002) 891-898
17. Schindler T.H., Nitzsche E.U., Olschewski M., Magosaki N., Mix M., Prior J.O., et al. Chronic inflammation and impaired coronary vasoreactivity in patients with coronary risk factors. Circulation 110 (2004) 1069-1075
18. Schindler T.H., Cardenas J., Prior J.O., Facta A.D., Kreissl M.C., Zhang X.L., et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 47 (2006) 1188-1195
19. Prior J.O., Quinones M.J., Hernandez-Pampaloni M., Facta A.D., Schindler T.H., Sayre J.W., et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 111 (2005) 2291-2298
20. Quinones M.J., Hernandez-Pampaloni M., Schelbert H., Bulnes-Enriquez I., Jimenez X., Hernandez G., et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 140 (2004) 700-708
21. Schindler T.H., Facta A.D., Prior J.O., Cadenas J., Hsueh W.A., Quinones M.J., et al. Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. Heart 93 (2007) 345-349
22. Cohn J.N., Quyyumi A.A., Hollenberg N.K., and Jamerson K.A. Surrogate markers for cardiovascular disease: functional markers. Circulation 109 Suppl 1 (2004) IV31-IV46
23. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 39 (1997) 287-324
24. Ludmer P.L., Selwyn A.P., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315 (1986) 1046-1051
25. Zeiher A.M., Drexler H., Wollschlager H., and Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 83 (1991) 391-401
26. Rossen J.D., Quillen J.E., Lopez A.G., Stenberg R.G., Talman C.L., and Winniford M.D. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol 18 (1991) 485-491
27. Nitzsche E.U., Choi Y., Czernin J., Hoh C.K., Huang S.C., and Schelbert H.R. Noninvasive quantification of myocardial blood flow in humans. A direct comparison of the [13N]ammonia and the [15O]water techniques. Circulation 93 (1996) 2000-2006
28. Mullani N.A., Goldstein R.A., Gould K.L., Marani S.K., Fisher D.J., O'Brien H.A., et al. Myocardial perfusion with rubidium-82. I. Measurement of extraction fraction and flow with external detectors. J Nucl Med 24 (1983) 898-906
29. Di Carli M.F., and Hachamovitch R. New technology for noninvasive evaluation of coronary artery disease. Circulation 115 (2007) 1464-1480
30. Sampson U.K., Dorbala S., Limaye A., Kwong R., and Di Carli M.F. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease. J Am Coll Cardiol 49 (2007) 1052-1058
31. Weinberg I.N., Huang S.C., Hoffman E.J., Araujo L., Nienaber C., Grover-McKay M., et al. Validation of PET-acquired input functions for cardiac studies. J Nucl Med 29 (1988) 241-247
32. Gambhir S.S., Schwaiger M., Huang S.C., Krivokapich J., Schelbert H.R., Nienaber C.A., et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med 30 (1989) 359-366
33. Bol A., Melin J.A., Vanoverschelde J.L., Baudhuin T., Vogelaers D., De Pauw M., et al. Direct comparison of [13N]ammonia and [15O]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres. Circulation 87 (1993) 512-525
34. Coffman J.D., and Gregg D.E. Reactive hyperemia characteristics of the myocardium. Am J Physiol 199 (1960) 1143-1149
35. Mosher P., Ross Jr. J., McFate P.A., and Shaw R.F. Control of coronary blood flow by an autoregulatory mechanism. Circ Res 14 (1964) 250-259
36. Czernin J., Muller P., Chan S., Brunken R.C., Porenta G., Krivokapich J., et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation 88 (1993) 62-69
37. Morita K., Tsukamoto T., Naya M., Noriyasu K., Inubushi M., Shiga T., et al. Smoking cessation normalizes coronary endothelial vasomotor response assessed with 15O-water and PET in healthy young smokers. J Nucl Med 47 (2006) 1914-1920
38. Tsukamoto T., Morita K., Naya M., Katoh C., Inubushi M., Kuge Y., et al. Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease. Eur J Nucl Med Mol Imaging 33 (2006) 1150-1156
39. Bergmann S.R., Herrero P., Markham J., Weinheimer C.J., and Walsh M.N. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol 14 (1989) 639-652
40. Chareonthaitawee P., Kaufmann P.A., Rimoldi O., and Camici P.G. Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. Cardiovasc Res 50 (2001) 151-161
41. Tamaki N., Yonekura Y., Senda M., Kureshi S.A., Saji H., Kodama S., et al. Myocardial positron computed tomography with 13N-ammonia at rest and during exercise. Eur J Nucl Med 11 (1985) 246-251
42. Senneff M.J., Geltman E.M., and Bergmann S.R. Noninvasive delineation of the effects of moderate aging on myocardial perfusion. J Nucl Med 32 (1991) 2037-2042
43. Prior J.O., Schindler T.H., Facta A.D., Hernandez-Pampaloni M., Campisi R., Dahlbom M., et al. Determinants of myocardial blood flow response to cold pressor testing and pharmacologic vasodilation in healthy humans. Eur J Nucl Med Mol Imaging 34 (2007) 20-27
44. Sawada S., Muzik O., Beanlands R.S., Wolfe E., Hutchins G.D., and Schwaiger M. Interobserver and interstudy variability of myocardial blood flow and flow-reserve measurements with nitrogen 13 ammonia-labeled positron emission tomography. J Nucl Cardiol 2 (1995) 413-422
45. Krivokapich J., Smith G.T., Huang S.C., Hoffman E.J., Ratib O., Phelps M.E., et al. 13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation 80 (1989) 1328-1337
46. Duvernoy C.S., Meyer C., Seifert-Klauss V., Dayanikli F., Matsunari I., Rattenhuber J., et al. Gender differences in myocardial blood flow dynamics: lipid profile and hemodynamic effects. J Am Coll Cardiol 33 (1999) 463-470
47. Wyss C.A., Koepfli P., Mikolajczyk K., Burger C., von Schulthess G.K., and Kaufmann P.A. Bicycle exercise stress in PET for assessment of coronary flow reserve: repeatability and comparison with adenosine stress. J Nucl Med 44 (2003) 146-154
48. Namdar M., Koepfli P., Grathwohl R., Siegrist P.T., Klainguti M., Schepis T., et al. Caffeine decreases exercise-induced myocardial flow reserve. J Am Coll Cardiol 47 (2006) 405-410
49. Schindler T.H., Nitzsche E.U., Olschewski M., Brink I., Mix M., Prior J., et al. PET-measured responses of MBF to cold pressor testing correlate with indices of coronary vasomotion on quantitative coronary angiography. J Nucl Med 45 (2004) 419-428
50. Jagathesan R., Barnes E., Rosen S.D., Foale R.A., and Camici P.G. Comparison of myocardial blood flow and coronary flow reserve during dobutamine and adenosine stress: implications for pharmacologic stress testing in coronary artery disease. J Nucl Cardiol 13 (2006) 324-332
51. Hernandez-Pampaloni M., Keng F.Y., Kudo T., Sayre J.S., and Schelbert H.R. Abnormal longitudinal, base-to-apex myocardial perfusion gradient by quantitative blood flow measurements in patients with coronary risk factors. Circulation 104 (2001) 527-532
52. Schindler T.H., Facta A.D., Prior J.O., Campisi R., Inubushi M., Kreissl M.C., et al. PET-measured heterogeneity in longitudinal myocardial blood flow in response to sympathetic and pharmacologic stress as a non-invasive probe of epicardial vasomotor dysfunction. Eur J Nucl Med Mol Imaging 33 (2006) 1140-1149
53. Zeiher A.M., Drexler H., Wollschlager H., and Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 84 (1991) 1984-1992
54. Nabel E.G., Ganz P., Gordon J.B., Alexander R.W., and Selwyn A.P. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 77 (1988) 43-52
55. Zeiher A.M., Drexler H., Saurbier B., and Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 92 (1993) 652-662
56. Campisi R., Czernin J., Schoder H., Sayre J.W., and Schelbert H.R. L-arginine normalizes coronary vasomotion in long-term smokers. Circulation 99 (1999) 491-497
57. Sato A., Terata K., Miura H., Toyama K., Loberiza Jr. F.R., Hatoum O.A., et al. Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. Am J Physiol 288 (2005) H1633-H1640
58. Zeiher A.M., Drexler H., Wollschlaeger H., Saurbier B., and Just H. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol 14 (1989) 1181-1190
59. Schwaiger M., Kalff V., Rosenspire K., Haka M.S., Molina E., Hutchins G.D., et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 82 (1990) 457-464
60. Di Carli M.F., Bianco-Batlles D., Landa M.E., Kazmers A., Groehn H., Muzik O., et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 100 (1999) 813-819
61. Di Carli M.F., Tobes M.C., Mangner T., Levine A.B., Muzik O., Chakroborty P., et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med 336 (1997) 1208-1215
62. Stevens M.J., Raffel D.M., Allman K.C., Dayanikli F., Ficaro E., Sandford T., et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 98 (1998) 961-968
63. Pop-Busui R., Kirkwood I., Schmid H., Marinescu V., Schroeder J., Larkin D., et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 44 (2004) 2368-2374
64. Kaufmann P.A., Gnecchi-Ruscone T., Yap J.T., Rimoldi O., and Camici P.G. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med 40 (1999) 1848-1856
65. Go V., Bhatt M.R., and Hendel R.C. The diagnostic and prognostic value of ECG-gated SPECT myocardial perfusion imaging. J Nucl Med 45 (2004) 912-921
66. Kubo S., Tadamura E., Toyoda H., Mamede M., Yamamuro M., Magata Y., et al. Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole. J Nucl Med 45 (2004) 730-738
67. Buus N.H., Bottcher M., Hermansen F., Sander M., Nielsen T.T., and Mulvany M.J. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 104 (2001) 2305-2310
68. Tawakol A., Forgione M.A., Stuehlinger M., Alpert N.M., Cooke J.P., Loscalzo J., et al. Homocysteine impairs coronary microvascular dilator function in humans. J Am Coll Cardiol 40 (2002) 1051-1058
69. Gould K.L., Nakagawa Y., Nakagawa K., Sdringola S., Hess M.J., Haynie M., et al. Frequency and clinical implications of fluid dynamically significant diffuse coronary artery disease manifest as graded, longitudinal, base-to-apex myocardial perfusion abnormalities by noninvasive positron emission tomography. Circulation 101 (2000) 1931-1939
70. De Bruyne B., Hersbach F., Pijls N.H., Bartunek J., Bech J.W., Heyndrickx G.R., et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "normal" coronary angiography. Circulation 104 (2001) 2401-2406
71. Lim M.J., and Kern M.J. Coronary pathophysiology in the cardiac catheterization laboratory. Curr Probl Cardiol 31 (2006) 493-550
72. Kern M.J. Coronary physiology revisited: practical insights from the cardiac catheterization laboratory. Circulation 101 (2000) 1344-1351
73. Drexler H., Zeiher A.M., Wollschlager H., Meinertz T., Just H., and Bonzel T. Flow-dependent coronary artery dilatation in humans. Circulation 80 (1989) 466-474
74. Cox D.A., Vita J.A., Treasure C.B., Fish R.D., Alexander R.W., Ganz P., et al. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 80 (1989) 458-465
75. Campisi R., Nathan L., Pampaloni M.H., Schoder H., Sayre J.W., Chaudhuri G., et al. Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration. Circulation 105 (2002) 425-430
76. Wyss C.A., Koepfli P., Namdar M., Siegrist P.T., Luscher T.F., Camici P.G., et al. Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia. Eur J Nucl Med Mol Imaging 32 (2005) 84-91
77. Kaufmann P.A., Gnecchi-Ruscone T., di Terlizzi M., Schafers K.P., Luscher T.F., and Camici P.G. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 102 (2000) 1233-1238
78. Wielepp P., Baller D., Gleichmann U., Pulawski E., Horstkotte D., and Burchert W. Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease. Eur J Nucl Med Mol Imaging 32 (2005) 1371-1377
79. Nagamachi S., Czernin J., Kim A.S., Sun K.T., Bottcher M., Phelps M.E., et al. Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET. J Nucl Med 37 (1996) 1626-1631
80. Siegrist P.T., Gaemperli O., Koepfli P., Schepis T., Namdar M., Valenta I., et al. Repeatability of cold pressor test-induced flow increase assessed with H(2)(15)O and PET. J Nucl Med 47 (2006) 1420-1426
81. Schindler T.H., Zhang X.L., Prior J.O., Cadenas J., Dahlbom M., Sayre J., et al. Assessment of intra- and interobserver reproducibility of rest and cold pressor test-stimulated myocardial blood flow with (13)N-ammonia and PET. Eur J Nucl Med Mol Imaging (2007) [E-pub ahead of print]
82. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
83. Jagathesan R., Kaufmann P.A., Rosen S.D., Rimoldi O.E., Turkeimer F., Foale R., et al. Assessment of the long-term reproducibility of baseline and dobutamine-induced myocardial blood flow in patients with stable coronary artery disease. J Nucl Med 46 (2005) 212-219
84. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 (2000) 840-844
85. Tomai F., Crea F., Gaspardone A., Versaci F., Ghini A.S., Chiariello L., et al. Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation 104 (2001) 1471-1476
86. Faxon D.P., Fuster V., Libby P., Beckman J.A., Hiatt W.R., Thompson R.W., et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 109 (2004) 2617-2625
87. Topol E.J., and Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101 (2000) 570-580
88. Bonetti P.O., Lerman L.O., and Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23 (2003) 168-175
89. Rozanski A., Gransar H., Wong N.D., Shaw L.J., Miranda-Peats R., Polk D., et al. Clinical outcomes after both coronary calcium scanning and exercise myocardial perfusion scintigraphy. J Am Coll Cardiol 49 (2007) 1352-1361
90. Nishimura R.A., Lerman A., Chesebro J.H., Ilstrup D.M., Hodge D.O., Higano S.T., et al. Epicardial vasomotor responses to acetylcholine are not predicted by coronary atherosclerosis as assessed by intracoronary ultrasound. J Am Coll Cardiol 26 (1995) 41-49
91. Schuijf J.D., Wijns W., Jukema J.W., Decramer I., Atsma D.E., de Roos A., et al. A comparative regional analysis of coronary atherosclerosis and calcium score on multislice CT versus myocardial perfusion on SPECT. J Nucl Med 47 (2006) 1749-1755
92. Madjid M., Toutouzas K., Stefanadis C., Willerson J.T., and Casscells S.W. Coronary thermography for detection of vulnerable plaques. J Nucl Cardiol 14 (2007) 244-249
93. Cury R.C., Nieman K., Shapiro M.D., Nasir K., Cury R.C., and Brady T.J. Comprehensive cardiac CT study: evaluation of coronary arteries, left ventricular function, and myocardial perfusion-is it possible?. J Nucl Cardiol 14 (2007) 229-243
94. Kaufmann P.A., Gnecchi-Ruscone T., Schafers K.P., Luscher T.F., and Camici P.G. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol 36 (2000) 103-109
95. Yokoyama I., Ohtake T., Momomura S., Nishikawa J., Sasaki Y., and Omata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 94 (1996) 3232-3238
96. Pitkanen O.P., Nuutila P., Raitakari O.T., Porkka K., Iida H., Nuotio I., et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 99 (1999) 1678-1684
97. Munzel T., Daiber A., Ullrich V., and Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 25 (2005) 1551-1557
98. Munzel T., and Keaney Jr. J.F. Are ACE inhibitors a "magic bullet" against oxidative stress?. Circulation 104 (2001) 1571-1574
99. Ohgushi M., Kugiyama K., Fukunaga K., Murohara T., Sugiyama S., Miyamoto E., et al. Protein kinase C inhibitors prevent impairment of endothelium-dependent relaxation by oxidatively modified LDL. Arterioscler Thromb 13 (1993) 1525-1532
100. May J.M. How does ascorbic acid prevent endothelial dysfunction?. Free Radic Biol Med 28 (2000) 1421-1429
101. Heller R., Unbehaun A., Schellenberg B., Mayer B., Werner-Felmayer G., and Werner E.R. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276 (2001) 40-47
102. Eckel R.H., Daniels S.R., Jacobs A.K., and Robertson R.M. America's children: a critical time for prevention. Circulation 111 (2005) 1866-1868
103. Campisi R., Czernin J., Schoder H., Sayre J.W., Marengo F.D., Phelps M.E., et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation 98 (1998) 119-125
104. Yokoyama I., Momomura S., Ohtake T., Yonekura K., Nishikawa J., Sasaki Y., et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 30 (1997) 1472-1477
105. Pitkanen O.P., Nuutila P., Raitakari O.T., Ronnemaa T., Koskinen P.J., Iida H., et al. Coronary flow reserve is reduced in young men with IDDM. Diabetes 47 (1998) 248-254
106. Di Carli M.F., Janisse J., Grunberger G., and Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 41 (2003) 1387-1393
107. Srinivasan M., Herrero P., McGill J.B., Bennik J., Heere B., Lesniak D., et al. The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. J Am Coll Cardiol 46 (2005) 42-48
108. Herrero P., Peterson L.R., McGill J.B., Matthew S., Lesniak D., Dence C., et al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 47 (2006) 598-604
109. Al Suwaidi J., Higano S.T., Holmes Jr. D.R., Lennon R., and Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37 (2001) 1523-1528
110. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3 (2006) 35-42
111. Avogaro A., and de Kreutzenberg S.V. Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta 360 (2005) 9-26
112. Bouloumie A., Marumo T., Lafontan M., and Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 13 (1999) 1231-1238
113. Vecchione C., Maffei A., Colella S., Aretini A., Poulet R., Frati G., et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 51 (2002) 168-173
114. Lembo G., Vecchione C., Fratta L., Marino G., Trimarco V., d'Amati G., et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 49 (2000) 293-297
115. Matsuda K., Teragawa H., Fukuda Y., Nakagawa K., Higashi Y., and Chayama K. Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res 26 (2003) 147-152
116. Winters B., Mo Z., Brooks-Asplund E., Kim S., Shoukas A., Li D., et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice. J Appl Physiol 89 (2000) 2382-2390
117. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88 (2001) E14-E22
118. Mancini G.B., Henry G.C., Macaya C., O'Neill B.J., Pucillo A.L., Carere R.G., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94 (1996) 258-265
119. Baller D., Notohamiprodjo G., Gleichmann U., Holzinger J., Weise R., and Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 99 (1999) 2871-2875
120. Czernin J., Barnard R.J., Sun K.T., Krivokapich J., Nitzsche E., Dorsey D., et al. Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation 92 (1995) 197-204
121. Fichtlscherer S., Breuer S., and Zeiher A.M. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient. Circulation 110 (2004) 1926-1932
122. Modena M.G., Bonetti L., Coppi F., Bursi F., and Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 40 (2002) 505-510
123. Peterson L.R., Eyster D., Davila-Roman V.G., Stephens A.L., Schechtman K.B., Herrero P., et al. Short-term oral estrogen replacement therapy does not augment endothelium-independent myocardial perfusion in postmenopausal women. Am Heart J 142 (2001) 641-647
124. Duvernoy C.S., Rattenhuber J., Seifert-Klauss V., Bengel F., Meyer C., and Schwaiger M. Myocardial blood flow and flow reserve in response to short-term cyclical hormone replacement therapy in postmenopausal women. J Gend Specif Med 4 (2001) 21-27 47
125. Guethlin M., Kasel A.M., Coppenrath K., Ziegler S., Delius W., and Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 99 (1999) 475-481
126. Huggins G.S., Pasternak R.C., Alpert N.M., Fischman A.J., and Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 98 (1998) 1291-1296
127. Janatuinen T., Laaksonen R., Vesalainen R., Raitakari O., Lehtimaki T., Nuutila P., et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 38 (2001) 561-568